FINWIRES · TerminalLIVE
FINWIRES

最新消息:Agnico Eagle透過三項獨立交易整合芬蘭中部拉普蘭綠岩帶,涉及Rupert、Aurion和B2Gold三家公司。

-- (第四段補充了關於B2Gold交易的更多細節,第五段和第六段補充了關於三項獨立交易的更多細節) Agnico Eagle Mines(紐約證券交易所和多倫多證券交易所代碼:AEM)週一宣布了一項計劃,旨在完成位於芬蘭北部中部拉普蘭綠岩帶的礦產整合,該計劃涉及就三項獨立交易達成最終協議。 這些交易包括:收購Rupert Resources Ltd.(多倫多證券交易所代碼:RUP.TO)所有已發行和流通在外的股份;收購Aurion Resources Ltd.(多倫多證券交易所代碼:AU.V)所有已發行和流通在外的股份;以及收購B2Gold Corp.(多倫多證券交易所代碼:BTO.TO)持有的Fingold Ventures Ltd. 70%的股份。加上Aurion持有的30%股份,Agnico Eagle將擁有Fingold合資公司100%的股權。 一份聲明指出,該公司目前持有Rupert公司13.9%的股份(未稀釋)和Aurion公司9.9%的股份(部分稀釋)。 根據協議,B2Gold已同意將Fingold公司70%的股份出售給Agnico,以換取3.25億美元的現金。此外,B2Gold和Agnico Eagle已同意就各自位於加拿大努納武特地區的金礦開採業務達成合作協議。 Agnico表示,這三項交易將使芬蘭走上未來十年內成為年產約50萬盎司黃金生產中心的道路;為開發極具前景的Ikkari金礦項目提供資金、技術和實地資源;並且“通過優化項目開發創造顯著價值,包括將Ikkari露天礦場延伸至Fingold合資區域,預計這將使礦山規劃在礦場邊界兩側捕獲更多黃金。” AEM補充道,這三項獨立交易整合了位於勘探程度較低的中拉普蘭綠岩帶內約2492平方公里的區域土地,從而「釋放了巨大的勘探潛力,並在各個勘探階段都擁有可靠的勘探目標」;同時,將Ikkari整合到公司現有的芬蘭平台,預計可帶來高達5億加元的運營、開發和邊界 Agnico Eagle總裁兼執行長Ammar Al-Joundi表示:「這些交易實現了我們長期的區域戰略,並依託我們在芬蘭20多年來積累的卓越運營經驗,在世界級金礦帶內打造了又一個擁有多個資產、持續數十年的平台。透過整合極具前景但勘探程度較低的中拉普蘭綠岩帶,我們將擁有長壽命的Kittila金礦、不受地界限制的涵蓋所有勘金礦探階段、目標明確的區域級土地整合在一起。 週一美國盤前交易中,AEM股價下跌1.1%,受美國股指期貨走低的影響。上週五,AEM在加拿大上漲2.3%,美國上漲2.4%。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA